Covista Inc

Covista Inc (CVSA) Stock Analysis

$131.820

+0.198 (+0.15%)At close

Loading chart…
High
132.580
Open
131.230
VWAP
131.71
Volume
250.02K
Mkt Cap
—
Low
130.735
Amount
32.93M
EV/EBITDA, TTM
9.69

Covista Inc., formerly Adtalem Global Education Inc., is a healthcare educator serving across five accredited institutions. Its institutions include American University of the Caribbean School of Medicine, Chamberlain University, Ross University School of Medicine, Ross University School of Veterinary Medicine and Walden University. It provides personalized, tech-enabled access to healthcare careers. Its American University of the Caribbean School of Medicine provides medical education with a focus on clinical experience across its two campuses in Sint Maarten and Preston, United Kingdom. Chamberlain University is an educator for nursing students in the United States, offering nursing and healthcare programs at over 24 campuses nationwide and online. Walden University provides healthcare education for working professionals through a range of online programs which include nursing, health sciences, public health and healthcare leadership.

AI analysis of Covista Inc (CVSA)

Buy

Covista Inc is a good buy right now due to its current price of $131.82, which is below the average analyst price target of $145. Additionally, the forward P/E ratio of 13.61 indicates that the stock is relatively undervalued compared to its earnings potential. The recent positive momentum is also supported by a 5-day change of +4.00% and a year-to-date change of +33.77%. However, a potential risk is the insider selling activity, with the CEO selling shares that accounted for 1.23% of his holdings, which could raise concerns about future performance.

Valuation Metrics

The current forward P/E ratio for Covista Inc (CVSA) is 13.61, compared to its 5-year average forward P/E of 14.35.

Forward P/E

Fair
5Y Average P/E
14.35
Current P/E
13.61
Overvalued
15.69
Undervalued
13.01

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
9.47
Current EV/EBITDA
9.69
Overvalued
10.18
Undervalued
8.75

Forward P/S

Fair
5Y Average P/S
1.98
Current P/S
2.00
Overvalued
2.10
Undervalued
1.86

Whales holding CVSA

Ö

ÖKoworld Lux S.A.

+ HoldingCVSA

+2.46%

3M Return

A

Ariel Investments, LLC

+ HoldingCVSA

-4.55%

3M Return

Events Timeline

2026-09-15 (ET)

09:30:00

Covista Invests $150,000 in THC to Expand Healthcare Career Exploration

2026-09-14 (ET)

08:30:00

Chamberlain University Appoints Jason Dunne as Chief Academic Officer

2026-08-06 (ET)

17:30:00

Sees FY27 Revenue at $2.05B-$2.09B

17:30:00

Covista Q4 Revenue of $501.4M Exceeds Expectations

2026-07-28 (ET)

08:30:00

Covista Appoints Emily Chiu and Leslie Storms to Board of Directors

News

CVSA FAQ — answered by Alphio AI

Covista Inc., formerly Adtalem Global Education Inc., is a healthcare educator serving across five accredited institutions. Its institutions include American University of the Caribbean School of Medicine, Chamberlain University, Ross University School of Medicine, Ross University School of Veterinary Medicine and Walden University. It provides personalized, tech-enabled access to healthcare careers. Its American University of the Caribbean School of Medicine provides medical education with a focus on clinical experience across its two campuses in Sint Maarten and Preston, United Kingdom. Chamberlain University is an educator for nursing students in the United States, offering nursing and healthcare programs at over 24 campuses nationwide and online. Walden University provides healthcare education for working professionals through a range of online programs which include nursing, health sciences, public health and healthcare leadership. It operates in the Academic & Educational Services sector.

Covista Inc is a good buy right now due to its current price of $131.82, which is below the average analyst price target of $145. Additionally, the forward P/E ratio of 13.61 indicates that the stock is relatively undervalued compared to its earnings potential. The recent positive momentum is also supported by a 5-day change of +4.00% and a year-to-date change of +33.77%. However, a potential risk is the insider selling activity, with the CEO selling shares that accounted for 1.23% of his holdings, which could raise concerns about future performance.

Community

More ↗

No posts yet

Sign up or log in to join the discussion

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Start trading